Docetaxel Injection
Product Images NDC 23155-905

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 19 technical images submitted to the FDA as part of the official labeling for Docetaxel (NDC 23155-905). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Heritage Pharmaceuticals Inc. D/b/a Avet Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

160mg-8ml-carton.jpg (160mg 8ml Carton)

160mg-8ml-carton.jpg (160mg 8ml Carton)
Docetaxel Injection 160 mg/8 mL (20 mg/mL) single-dose vial carton from Avet Pharmaceuticals Inc. The label states it is ready to add to infusion solution for intravenous use and includes manufacturing details by Sichuan Huiyu Pharmaceutical Co., Ltd. It also contains handling instructions, storage conditions (2-25 °C, protect from light), and a barcode.*
FDA Label Image

160mg-8ml-vial.jpg (160mg 8ml Vial)

160mg-8ml-vial.jpg (160mg 8ml Vial)
Label for Docetaxel Injection 160 mg/8 mL (20 mg/mL) intravenous injection by Avet Pharmaceuticals Inc. The label indicates an 8 mL single-dose vial for intravenous use only, ready to add to infusion solution, with instructions to discard unused portion and see the package for complete instructions. The label includes a barcode and manufacturer details.*
FDA Label Image

20mg-ml-carton (20mg mL Carton)

20mg-ml-carton (20mg mL Carton)
The packaging label for Docetaxel Injection 20 mg/mL by Avet Pharmaceuticals. This 1 mL single-dose vial is indicated for intravenous use and is ready to add to infusion solution. The label includes manufacturer information for Sichuan Huiyu Pharmaceutical Co., Ltd. in China and Avet Pharmaceuticals Inc. Bar code and storage instructions (2-25°C) are visible, as well as warnings and usage directions on discarding unused portions.*
FDA Label Image

20mg-ml-vial.jpg (20mg mL Vial)

20mg-ml-vial.jpg (20mg mL Vial)
Label for Docetaxel Injection 20 mg/mL, an intravenous human prescription drug by Avet Pharmaceuticals Inc. The label specifies a 1 mL single-dose vial and indicates it is ready to add to an infusion solution. Directions include discarding unused portions and referring to package inserts for instructions.*
FDA Label Image

80mg-4ml-carton.jpg (80mg 4ml Carton)

80mg-4ml-carton.jpg (80mg 4ml Carton)
Package label for Docetaxel Injection 80 mg/4 mL (20 mg/mL) by Avet Pharmaceuticals. The label indicates it is ready to add to infusion solution for intravenous use only. It includes manufacturer and distributor details, dosage form, and storage instructions, with a barcode and warnings about discard of unused vial portions.*
FDA Label Image

80mg-4ml-vial.jpg (80mg 4ml Vial)

80mg-4ml-vial.jpg (80mg 4ml Vial)
Label for Docetaxel Injection 80 mg/4 mL (20 mg/mL) single-dose vial by Avet Pharmaceuticals Inc. It indicates intravenous use only and readiness for infusion solution. The label includes manufacturing details, discard instructions, and a barcode.*
FDA Label Image
FDA Label Image
FDA Label Image

Figure 1 (Figure 1)

Figure 1 (Figure 1)
A Kaplan-Meier curve chart depicting Disease-Free Survival (DFS) Probability (%) over time in months for two treatment groups labeled as TAC and FAC. The graph shows DFS probability decreasing over approximately 66 months for both groups, with the TAC group generally demonstrating higher survival probabilities compared to the FAC group.*
FDA Label Image

Figure 10 (Figure 10)

Figure 10 (Figure 10)
A survival curve chart showing survival probability (%) over survival time in months for two groups: TPF (n=255) and PF (n=246). The chart includes stepwise lines illustrating survival trends and a table below listing the number of patients at risk over time for each group.*
FDA Label Image

Figure 2 (Figure 2)

Figure 2 (Figure 2)
A survival curve chart depicting survival probability (%) over survival time (months) for two groups labeled TAC and FAC. The x-axis represents survival time in months, ranging from 0 to 66, and the y-axis represents survival probability from 0% to 100%. Two lines illustrate survival trends for the TAC and FAC groups over time.*
FDA Label Image

Figure 3 (Figure 3)

Figure 3 (Figure 3)
A survival curve chart depicting cumulative probability over survival time in months. Two groups are compared, labeled T75 and VI, with a survival time range from 0 to 21 months. The chart includes a log-rank p-value of 0.13 indicating statistical comparison of overall survival between the groups.*
FDA Label Image

Figure 4 (Figure 4)

Figure 4 (Figure 4)
A survival curve graph showing cumulative probability versus survival time in months for two groups labeled T75 and V/I. The plot compares overall survival with a log-rank p-value of 0.13, indicating no significant difference between the two curves over a 21-month period.*
FDA Label Image

Figure 5 (Figure 5)

Figure 5 (Figure 5)
A survival probability chart showing survival time in months on the x-axis and survival probability on the y-axis. Two curves are displayed, one labeled T75 q3w (solid line) and the other M q3w (dotted line), illustrating differing survival probabilities over a 30-month period.*
FDA Label Image

Figure 6 (Figure 6)

Figure 6 (Figure 6)
A Kaplan-Meier survival curve illustrating probability over time in months, comparing two groups labeled TCF and CF. The vertical axis shows probability percentage from 0 to 100%, and the horizontal axis shows time in months from 0 to 24. The chart shows decreasing survival probabilities for both groups over time.*
FDA Label Image

Figure 7 (Figure 7)

Figure 7 (Figure 7)
A Kaplan-Meier survival curve graph comparing survival probability (%) over time in months for two groups labeled TCF and CF. The x-axis represents survival time in months (0 to 36), and the y-axis shows survival probability from 0 to 100%. Two stepwise curves depict the survival trends for each group.*
FDA Label Image

Figure 8 (Figure 8)

Figure 8 (Figure 8)
A Kaplan-Meier survival curve chart showing progression-free survival (PFS) probability over time in months. The solid line represents the TPF group, while the dashed line represents the PF group, comparing their PFS probabilities from 0 to 42 months.*
FDA Label Image

Figure 9 (Figure 9)

Figure 9 (Figure 9)
A survival probability graph depicting survival time in months on the x-axis and survival probability percentage on the y-axis. The graph compares two groups labeled TPF and PF, represented by a solid line and a dashed line respectively, showing declining survival probabilities over time for both groups.*
FDA Label Image

Structural Formula (Structural Formula)

Structural Formula (Structural Formula)
Chemical structure of Docetaxel, showing its complex molecular arrangement including multiple rings, hydroxyl groups, and ester linkages consistent with its taxane class.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.